Treat Autosomal Dominant Polycystic Kidney Disease With Oral Ketone Ester?

NCT06100133 | Unknown Phase 2 DMC

• 1 other identifier: NEFADPKD1
• Study Type: interventional
• Target: 20
• Locations: 0 countries
• Sites: N/A

Brief Summary

The investigators are running a study to see if a special drink, called a "ketone ester", can help people with a type of kidney disease named "Autosomal Dominant Polycystic Kidney Disease" or ADPKD for short. The investigators want to find out: If it's easy for patients to take this drink every day for about 2 months. If it's safe and doesn't cause any problems. If it makes a difference in the size and function of the kidneys. Who can join? People between 16 to 70 years old who have ADPKD. Those with a certain amount of kidney size and function. People who haven't been on specific diets or lost a lot of weight recently. Women who are not breastfeeding and are using birth control. People with a body weight that is not too low or too high. Who cannot join? People who've been on a high-fat diet or skipped meals for a while recently. Those with other health conditions like diabetes or certain metabolic issues. Anyone who has a problem with getting an MRI scan. If participants are in another medical study right now. The study will happen in two Belgian hospitals and is supported by the UZ Brussel's nephrology department. The investigators hope to include 20 people and start in November 2023.

Conditions

ADPKD

Keywords

ketone ester

Outcome Measures

Primary Outcomes (2)

• Observance

  Objective observance (ketone body levels ≥0.8 mmol/l in ≥75% of blood measurements and ≥60% of maximal theoretic dose determined by used packages and self-report)

  56 days

• Feasibility

  Patient reported feasibility, defined as a cohen d effect size of \< 0.5 in the ADPKD impact scale.Both targets (observance and self-reported feasibility) must be met to reach the endpoint.

  56 days

Secondary Outcomes (2)

• Total Kidney Volume

  56 days

• Kidney Function

  56 days

Study Arms (1)

Ketone Ester

EXPERIMENTAL

Up to 100g ketone ester daily for 56 days

Dietary Supplement: Ketone ester

Interventions

Ketone ester DIETARY_SUPPLEMENT

Up to 100g ketone ester daily for 56 days

Also known as: (R)-3-hydroxybutyl (R)-3-hydroxybutyrate (Ketone Ester)

Ketone Ester

Eligibility Criteria

• Age: 16 Years - 70 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• \- ADPKD patients (diagnosis based on genetics or imaging) ≥ 16 and ≤ 70 years.
• Total Kidney Volume ≥ 600 mL.
• eGFR (CKD-EPI) ≥ 30 ml/min/1.73m2.
• Normal blood glucose, HbA1C and ketones.
• Women of childbearing potential who are non-lactating and using an effective form of birth control.
• Stable disease-modifying treatment for the last 2 months.
• Well controlled hypertension (stable antihypertensive medications for at least 2 months).
• BMI \> 18 \< 30.
• Written informed consent.

You may not qualify if:

• Diabetes mellitus.
• Conditions prohibiting the use of a ketogenic diet (liver damage, pancreatic failure, pyruvate-carboxylase deficiency, defects in fatty acid oxidation/gluconeogenesis/ketolysis/neogenesis, hyperinsulinism), based on patient history.
• Diagnosis with any disorder of fatty acid metabolism based on patient history.
• Eating disorder.
• Alcohol abuse.
• Contraindication for MRI.
• Participation in other interventional trial.

Sponsors & Collaborators

• Universitair Ziekenhuis Brussel: lead

MeSH Terms

Conditions

Polycystic Kidney, Autosomal Dominant

Interventions

formic acid 4-(3-oxobutyl)phenyl ester

Condition Hierarchy (Ancestors)

Polycystic Kidney Diseases; Kidney Diseases, Cystic; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Abnormalities, Multiple; Congenital Abnormalities; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Ciliopathies; Genetic Diseases, Inborn

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: Repeated measures design to register the changes before and after treatment. Non-randomized, non-blinded, multi center prospective interventional cohort trial.

Study Record Dates

• First Submitted: September 29, 2023
• First Posted: October 25, 2023
• Study Start: November 1, 2023
• Primary Completion: December 1, 2024
• Study Completion: July 1, 2025
• Last Updated: October 25, 2023

Record last verified: 2023-09